Floatz logo

Docetaxel

Prostate Neoplasm

Merck Sharp & Dohme LLCSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
73/ 100
Competitive Position
73/ 100

Competitive context

69 Active assets in the Prostate Neoplasm cohort.

Asset / SponsorPhaseRating
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
Prednisone
Merck Sharp & Dohme LLC
Phase 3BBB
Abiraterone
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Leuporelin
Dana-Farber Cancer Institute
Phase 4BB
RADIUM RA-223
Bayer
Phase 3BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative · Phase 2
72 / 100
View asset →
pancreatic adenocarcinomaActive
BBB
Indicative · Phase 2
72 / 100
View asset →
prostate adenocarcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →